Goldline Pharmaceutical IPO Subscribed 840.50 Times on Day 3
5paisa Capital Ltd
- 2 min read
Last Updated: 14th May 2026 - 05:21 pm
Goldline Pharmaceutical Limited's initial public offering (IPO) closed its three-day subscription window with exceptional investor interest, reaching 840.50 times overall subscription by 4:59 PM on Day 3 (May 14, 2026). The ₹11.61 crore book-build issue, priced at ₹41 to ₹43 per share, received bids for 1,53,81,06,000 shares against 18,30,000 shares on offer, with total applications reaching 1,66,522.
Invest in Indian Markets and Unlock Future Potential With 5paisa!Subscription Status of Goldline Pharmaceutical IPO
| Date | QIB | NII | Individual Investors | Total |
|---|---|---|---|---|
| Day 1 (May 12) | 1.31 | 24.46 | 34.07 | 22.35 |
| Day 2 (May 13) | 1.31 | 146.12 | 139.51 | 100.14 |
| Day 3 (May 14) | 180.22 | 1,661.99 | 880.68 | 840.50 |
Here are the subscription details for Goldline Pharmaceutical IPO Day 3, as of 5:04 PM:
| Investor Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (₹ Cr.) |
|---|---|---|---|---|
| Anchor Investors | 1.00 | 7,32,000 | 7,32,000 | 8.04 |
| Market Maker | 1.00 | 1,38,000 | 1,38,000 | 2.91 |
| QIB (Ex-Anchor) | 180.22 | 5,40,000 | 9,73,17,000 | 902.28 |
| NII | 1661.99 | 3,90,000 | 64,81,77,000 | 1,535.71 |
| Individual Investors | 880.68 | 9,00,000 | 79,26,12,000 | 1,367.78 |
| Total | 840.50 | 18,30,000 | 1,53,81,06,000 | 3,805.77 |
Key Highlights – Day 3
- Overall subscription surged to 840.50 times on the final day, from Day 2's 100.14 times, driven by a sharp last-day surge across all investor categories.
- Non-institutional investors led with extraordinary demand at 1,661.99 times, surging from Day 2's 146.12 times.
- Individual investors recorded strong participation at 880.68 times, surging from Day 2's 139.51 times.
- Qualified institutional buyers (ex-anchor) surged to 180.22 times from Day 2's 1.31 times, indicating heavy institutional interest concentrated on the closing day.
Key Highlights – Day 2
- Overall subscription crossed full subscription at 100.14 times, surging from Day 1's 22.35 times.
- Non-institutional investors surged to 146.12 times from Day 1's 24.46 times, with bNII at 159.99 times and sNII at 119.02 times.
- Individual investors surged to 139.51 times from Day 1's 34.07 times.
- Qualified institutional buyers (ex-anchor) held steady at 1.31 times, unchanged from Day 1.
Key Highlights - Day 1
- Overall subscription reached 22.35 times on Day 1 (May 12, 2026), reflecting strong initial investor interest in this pharmaceutical marketing SME IPO.
- Individual investors led opening participation at 34.07 times on Day 1.
- Non-institutional investors recorded strong demand at 24.46 times, with bNII at 22.52 times and sNII at 28.25 times on Day 1.
- Qualified institutional buyers (ex-anchor) crossed full subscription at 1.31 times on Day 1.
- Anchor investors fully subscribed their allocation of ₹3.15 crores on May 11, 2026.
About Goldline Pharmaceutical Limited
Goldline Pharmaceutical Limited is engaged in the marketing of pharmaceutical products under the brand "Goldline" across five divisions covering therapeutic areas including physicians, orthopaedics, cardiology, diabetology, paediatrics, and critical care. The company operates an asset-light model through third-party manufacturers and a network of 15 manufacturers and seven distributors.
- FREE IPO Application
- Apply with Ease
- Pre-Apply for IPOs
- UPI Bid Instantly
Trending on 5paisa
5paisa Capital Ltd
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.